ViaCyte is a regenerative medicine company focused on developing a transformative cell replacement therapy to free people with insulin-requiring diabetes from painful and frequent insulin injections, strict diet regimens, constant blood sugar monitoring, and serious chronic health conditions associated with the disease.
ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels.
|HQ||San Diego, CA, US||Map|
|Employees (est.) (May 2021)||103||(+7%)|
ViaCyte total Funding
ViaCyte latest funding size
Time since last funding
|a year ago|
|TPG, Johnson & Johnson Development Corporation, TPG Capital, Sanderling Ventures, W.L. Gore & Associates, RA Capital Management, Johnson & Johnson Innovation, Bain Capital Life Sciences, Asset Management Partners, JDRF|
ViaCyte has 2.21k Twitter Followers. The number of followers has increased 0.8% month over month and increased 3.6% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was ViaCyte founded?
ViaCyte was founded in 1999.
Who are ViaCyte key executives?
ViaCyte's key executives are Ian F. Smith, Paul Laikind and Brittany K. Bradrick.
How many employees does ViaCyte have?
ViaCyte has 103 employees.
Who are ViaCyte competitors?
Competitors of ViaCyte include Kowa Pharmaceuticals America, Profil and Thermalin.
Where is ViaCyte headquarters?
ViaCyte headquarters is located at 3550 General Atomics Ct, San Diego.
Where are ViaCyte offices?
ViaCyte has an office in San Diego.
How many offices does ViaCyte have?
ViaCyte has 1 office.
Receive alerts for 300+ data fields across thousands of companies